Abeona Therapeutics Inc. (PCJ.F)

3,9000 +0,7800 (+25,00%) Börsenschluss: 06:30PM CEST

Abeona Therapeutics Inc.

6555 Carnegie Avenue
4th Floor
Cleveland, OH 44103
United States
646 813 4701
https://www.abeonatherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 84

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Vishwas Seshadri M.B.A., Ph.D.	President, CEO & Director	1,39M	N/A	1976
Dr. Brendan M. O'Malley J.D., Ph.D.	Senior VP & General Counsel	749,2k	N/A	1970
Mr. Brian Kevany Ph.D.	Senior VP, CTO & CSO	N/A	N/A	N/A
Mr. Gregory Gin	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Alison Hardgrove	Vice President of Human Resources	N/A	N/A	N/A
Mr. Jon Voss	VP & Head of Quality	N/A	N/A	1960
Mr. Dmitriy Grachev M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A
Dr. Madhav Vasanthavada M.B.A., Ph.D.	Senior VP, Chief Commercial Officer & Head of Business Development	N/A	N/A	N/A
Mr. Carl Denny	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Corporate Governance

Abeona Therapeutics Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.